NeuroSearch Announces Breakthrough Tesofensine Results

NeuroSearch A/S has concluded a Phase IIb Proof-of-Concept and dose finding study, TIPO-1, with its drug candidate tesofensine for the treatment of obesity with very positive results. Data from the study in 203 patients show that 24 weeks' treatment with 0.25 mg, 0.5 mg and 1 mg tesofensine resulted in a dose-dependent average weight loss of 6.5%, 11.2% and 12.6%, respectively, against a weight loss of 2.0% in the placebo group.

Secondary end-points, including relative reduction in BMI as well as feeling of satiety and appetite were also met. In the two highest dose groups treatment with tesofensine led to an average reduction in the patients' BMI of 4.

The combined clinical safety data base from five individual studies with tesofensine now counts approximately 1,000 patients exposed to relevant therapeutic doses. This safety backing together with the breakthrough weight-loss results from the TIPO-1 study as well as weight-loss data from previous clinical studies support the preparation for a pivotal clinical Phase III programme with tesofensine for the treatment of obesity with a clear guidance for final dosing regimes.

For further information please contact:

Flemming Pedersen,

CEO

Tel: +45 44 60 82 14

Email: ns@neurosearch.dk